AAVantgarde Bio Srl of Italy has raised €61 million in a Series A financing to develop genetic medicines for inherited retinal diseases. The financing was co-led by Atlas Venture of the US and Netherlands-based Forbion. ---Subscribe to MedNous to access this article--- Regenerative Medicine Company News Finance, Grants, Deals
